Neurotrophic Factors in the Treatment of Peripheral Neuropathy

  1. Gregory R. Bock Organizer and
  2. Jamie A. Goode
  1. Stuart C. Apfel and
  2. John A. Kessler Chairman

Published Online: 28 SEP 2007

DOI: 10.1002/9780470514863.ch8

Ciba Foundation Symposium 196 - Growth Factors as Drugs for Neurological and Sensory Disorders

Ciba Foundation Symposium 196 - Growth Factors as Drugs for Neurological and Sensory Disorders

How to Cite

Apfel, S. C. and Kessler, J. A. (2007) Neurotrophic Factors in the Treatment of Peripheral Neuropathy, in Ciba Foundation Symposium 196 - Growth Factors as Drugs for Neurological and Sensory Disorders (eds G. R. Bock and J. A. Goode), John Wiley & Sons, Ltd., Chichester, UK. doi: 10.1002/9780470514863.ch8

Author Information

  1. Department of Neurology, Albert Einstein College of Medicine, 1410 Pelham Parkway South, Bronx, NY 10461, USA

Publication History

  1. Published Online: 28 SEP 2007

ISBN Information

Print ISBN: 9780471957218

Online ISBN: 9780470514863

SEARCH

Keywords:

  • insulin-like growth factor 1;
  • peripheral neuropathy;
  • nerve growth factor;
  • polyneuropathy;
  • peripheral nervous system

Summary

Peripheral neuropathies are common and frequently debilitating disorders which may include various subpopulations of motor, sensory or autonomic neurons depending on the underlying aetiology. They are likely to be the first group of neurological disorders to be successfully treated with growth factors since peripheral nerves are accessible to proteins given systemically. Preclinical and ongoing clinical trials of nerve growth factor (NGF) suggest that it will be useful for the treatment of diabetic, toxic and compressive sensory neuropathies. At appropriate doses NGF has no significant side effects in humans. Since NGF administration to mature animals stimulates synthesis of brain-derived neurotrophic factor and perhaps other neurotrophins in peripheral nerves, the spectrum of neuropathies treatable with NGF is wider than might be predicted. Preclinical studies suggest that insulin-like growth factor 1 (IGF-1) will be useful for the treatment of mixed motor and sensory neuropathies. For example, IGF-1 treatment can prevent the experimental motor and sensory neuropathies caused by the antitumour drugs, vincristine and cisplatin. Other neurotrophic factors have also shown promise in preclinical trials. The successful use of growth factors in the treatment of peripheral neuropathies may provide the first true therapy for this previously untreatable and devastating group of neurological disorders.